Suvretta Capital Management, LLC Immunovant, Inc. Transaction History

Suvretta Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$13.08 - $49.6 $3.39 Million - $12.9 Million	-259,200 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$36.36 - $52.71 $10 Million - $14.6 Million	-276,084 Reduced 51.58%	259,200 $12 Million
Q3 2020 Nov 16, 2020	BUY	$22.61 - $38.9 $8.31 Million - $14.3 Million	367,400 Added 218.84%	535,284 $18.8 Million
Q2 2020 Aug 14, 2020	BUY	$13.87 - $28.44 $1.83 Million - $3.75 Million	131,784 Added 365.05%	167,884 $4.09 Million
Q1 2020 May 15, 2020	BUY	$8.36 - $17.13 $301,796 - $618,393	36,100 New	36,100 $562,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Suvretta Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Suvretta Capital Management, LLC with notifications on news.